112例甲泼尼龙琥珀酸钠致过敏性报告分析

doi:10.19803/j.1672-8629.2021.02.12

摘要/Abstract

摘要： 目的探讨甲泼尼龙琥珀酸钠致过敏反应的发生特点与规律,为临床安全、合理用药提供依据和参考。方法通过回顾性研究,2013年1月1日至2019年10月31日该市收集的112例甲泼尼龙琥珀酸钠致过敏反应报告进行整理分析。结果 112例患者中男女比例为1.6∶1,0~3岁的占66.07%;原患疾病以呼吸系统为主,占67.87%;过敏反应以皮肤及其附件损害最多见（74.63%）;96.43%的不良反应发生在用药当天,71.43%发生在用药后30 min内;110例患者经对症处理后好转或痊愈。结论临床需重视甲泼尼龙琥珀酸钠引起的过敏反应,一旦出现,需立即停药,并根据病情做对症处理。

关键词: 甲泼尼龙琥珀酸钠, 过敏反应, 合理用药

Abstract: Objective To investigate the characteristics and regularity of hypersensitivity caused by methylprednisolone sodium succinate in order to provide reference for rational clinical use of drugs. Methods The data on 112 cases of ADRs induced by methylprednisolone sodium succinate that was collected by Weifang Center for ADR Monitoring between January 2013 and October 2019 was analyzed. Results Among the 112 patients, the ratio of males to females was 1.6:1, and 66.07% of them were 0-3 years old. The preexisting diseases mostly involved the respiratory system, accounting for 67.87% of the total. The most common manifestations of hypersensitivity were the damage to the skin and its accessories (74.63%). Meanwhile, 96.43% of the ADRs occurred on the day of administration, and 71.43% within 30 minutes. In the end, 110 patients were improved/cured after symptomatic treatment. Conclusion The hypersensitivity induced by methylprednisolone sodium succinate deserves more attention. Administration should be discontinued soon after ADRs occur and symptomatic treatment should start without delay.

Key words: methylprednisolone sodium succinate, hypersensitivity, rational use of drugs

中图分类号:

R994.11

陈焕蕾, 李宁, 郑雪玲. 112例甲泼尼龙琥珀酸钠致过敏性报告分析[J]. 中国药物警戒, 2021, 18(2): 155-159.

CHEN Huanlei, LI Ning, ZHENG Xueling. 112 Cases of Hypersensitivity Induced by Methylprednisolone Sodium Succinate[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 155-159.

参考文献

[1] Yalkowsky SH, Yan H.Handbook of aqueous solubility data [M]. Florida: CRC Press, 2010: 1-1513.
[2] Jia YC, Peng YX.The preparation and quality study of methylpred-nisolone sodium succinate for injection[J]. Chinese Pharmaceutical Affairs(中国药事), 2016, 30(8): 808-814.
[3] An N, Wang XY.Nursing care of a case of allergic reaction caused by methylprednisolone sodium succinate for injection[J]. Chinese Journal of Misdiagnostics(中国误诊学杂志), 2020, 10(8): 1971-1972.
[4] Zhu LP.Nursing experience of 38 cases of methylprednisolone induced anaphylactic shock[J]. China Pharmaceuticals(中国药业), 2013, 22(11): 100-101.
[5] Demoly P, Adkinson NF, Brockow K, et al.International consensus on drug allergy[J]. Allergy, 2014, 69(4): 420-437.
[6] Shi XP, Lgu QZ, Pan W.Two cases of intractable hiccup caused by intravenous injection of high dose methylprednisolone[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2018, 27(5): 363-364.
[7] Jiang BB, Zhang JG, Wang QF, et al.A case of allergic reaction induced by methylprednisolone[J]. Clinical Misdiagnosis & Mistherapy(临床误诊误治), 2014, 27(12): 98.
[8] Huang WX, Pu XP, Jin GL, et al.Anaphylactic shock induced by methylprednisolone sodium succinate for injection in one patient[J]. Herald of Medicine(医药导报), 2015, 34(7): 898.
[9] Wang XH, Wang QQ, He ZF, et al.Severe allergic reaction caused by methylprednisolone sodium succinate for injection in one patient[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2017, 36(6):370-372.
[10] Shen W, Yuan Ling, Li S, et al.Analysis on 22 cases of methylpredniso-lone succinate induced immediate hypersensitivity[J]. China Pharmacist(中国药师), 2018, 21(7): 1234-1236.
[11] Yang L, Liu GH.Pathogenesis and in vitro detection of drug allergy[J]. Chinese Journal of Allergy and Clinical Immunology(中华临床免疫和变态反应杂志), 2012, 6(2): 152-157.
[12] Sun JW.Effect of methylprednisolone on acute attack of chronic obstructive pulmonary disease[J]. Clinical Medicine(临床医学), 2008, 28(12): 35-36.
[13] Knarborg M, Bendstrup E, Hilberg O.Increasing awareness of corticosteroid hypersensitivity reactions is important[J]. Respirol Case Rep, 2013, 1(2): 43-45.
[14] Mendelson LM, Meltzer EO, Hamburger RN.Anaphylaxis-like reactions to corticosteroid therapy[J]. J Allergy Clin Immunol, 1974, 54(3): 125-131.
[15] Burgdorff T, Venemalm L, Vogt T, et al.IgE-mediated anaphylactic reaction induced by succinate ester of methylpredni-solone[J]. Ann Allergy Asthma Immunol, 2002, 89(4): 425-428.
[16] Nucera E, Lombardo C, Aruanno A, et al.“Empty sella syndrome”: a case of a patient with sodium succinate hydrocortisone allergy[J]. Eur J Endocrinol, 2011, 164(1): 139-140.
[17] Xiang WZ, Xu AE, Song XZ, et al.Research progress of glucocorticoid-induced local contact allergy and systemic allergy[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2007, 40(7): 449-452.
[18] Rao LJ, Kong FF, Guo LJ.A case report of hypokalemia induced by methylprednisolone sodium succinate pulse therapy[J]. Chinese Journal of Modern Drug Application(中国现代药物应用), 2013, 7(3): 97-98.
[19] Yang XY, Xiao XL, Xiao LT.Abnormal psychiatric symptoms associated with intravenous methylprednisolone infusion[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2009, 11(4): 277-278.
[20] Wan XF, Hui Y.Three Cases of serious cardiac adverse reactions caused by methylprednisolone impulse therapy[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2009, 42(11): 789-791.
[21] Zheng C, Mei D, Wang L, et al.Concern about adverse reactions of excipients in preparations[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2005, 40(9): 644-649.
[22] Lv QJ, Cao P.Adverse reactions and safety management of pharmaceutical excipients[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2010, 12(6): 410-414.
[23] Li QS, Wei QY.Interpretation of guidelines from the european academy of allergy and clinical immunology for anaphylaxis[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2015, 35(8): 686-690.
[24] Zhang MJ, Luo M.A case report of anaphylaxis induced by prednisone acetate tablets and sodium hydrocortisone succinate for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(4): 255-256.
[25] Yang H, Yin DH.Pharmaceutical practice of a case of minimally pathological nephropathy with severe hypokalemia caused by glucocorticoids[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(7): 425-429.